证券代码：300326 证券简称：ST 凯利 公告编号：2025-049 上海凯利泰医疗科技股份有限公司 关于2024年度股东大会增加临时提案暨股东大会补充通知 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于2025年4月28日 召开第六届董事会第三次会议，审议通过《关于提请召开公司2024年度股东大 会的议案》，定于2025年6月6日召开公司2024年度股东大会，具体内容详见刊 登在中国证监会指定信息披露网站上的《上海凯利泰医疗科技股份有限公司关 于召开2024年度股东大会的通知》。 2025年5月16日，公司董事会收到持股1%以上股东上海凯诚君泰投资有限 公司以书面形式提交的《关于增加2024年度股东大会临时提案的函》；2025年5 月16日，公司董事会收到持股1%以上股东涌金投资控股有限公司以书面形式提 交的《关于增加2024年度股东大会临时提案的函》。 现就收到股东提议增加2024年度股东大会临时提案函的情况以及股东大会 补充通知的情况公告如下： 一、收到股东提议增加2024年度股东大会临时 ...

独立董事候选人声明与承诺 声明人刘学文作为上海凯利泰医疗科技股份有限公司 第六届董事会独立董事候选人，已充分了解并同意由提名 人上海凯诚君泰投资有限公司提名为上海凯利泰医疗科技 股份有限公司（以下简称"公司"）第六届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在 任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立 董事候选人任职资格及独立性的要求，具体声明如下： 一、已经通过上海凯利泰医疗科技股份有限公司第六 届董事会提名委员会资格审查，提名人与本人不存在利害 关系或者其他可能影响独立履职情形的密切关系。 □ 是 ☑ 否 如否，请详细说明：由上海凯诚君泰投资有限公司（持 有上海凯利泰医疗科技股份有限公司 3.51%股份）提名，提 交股东大会审议，相关资料本人已提交承诺书，承诺真实 有效。 二、本人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办 1 上海凯利泰医疗科技股 ...

上海凯利泰医疗科技股份有限公司 二、监事会对公司 2024 年度有关事项的意见 2024 年度监事会工作报告 2024 年，上海凯利泰医疗科技股份有限公司（以下简称"公司"）监事会严 格按照《公司法》、《公司章程》、《深圳证券交易所上市公司自律监管指引第 2 号-创业板上市公司规范运作指引》、《监事会议事规则》等有关法律法规及公司 内控制度的要求，从切实维护公司利益和广大股东权益出发，认真履行了监督职 责。监事会成员通过列席董事会和股东大会会议，对重大决策事项进行监督，对 公司财务状况及董事、高管人员履职情况进行监督，确保公司能够规范、有序的 运作。现将监事会在报告期内的工作情况报告如下： | | | 会议时间 | | 会议名 | 审议内容 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 称 | | | | | 2024 | 年 | 4 | 第五届 监事会第十 | | 1、《关于子公司实施股权激励暨放弃优先认 | | 月 1 | 日 | | | | 购权的议案》 | | | | | | | 三次会议 | | | | | | | | | 1、《 ...

上海凯利泰医疗科技股份有限公司独立董事提名人声明 提名人上海凯诚君泰投资有限公司现就提名刘学文为 上海凯利泰医疗科技股份有限公司第六届董事会独立董事 候选人发表公开声明。被提名人已书面同意作为上海凯利 泰医疗科技股份有限公司第六届董事会独立董事候选人 （参见该独立董事候选人声明）。本次提名是在充分了解 被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为 被提名人符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格 及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过公司第六届董事会提名委员会 资格审查， 提名人与被提名人不存在利害关系或者其他可 能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 1 三、被提名人符合中国证监会《上市公司独立董事管 理办法》和深圳证券交易所业务规则规定的独立董事任职 资格和条件。 ☑ 是 □ 否 如否，请详细说明：______________________________ 四、被提名人符合公司章程 ...

Revenue Performance - The company achieved a revenue of 984,518,762.54 yuan in 2024, representing a year-on-year growth of 2.96% [2] - Revenue from the medical device manufacturing segment was 559,409,042.90 yuan, accounting for 56.83% of total revenue, with a slight decline of 0.83% [2] - Revenue from medical device trading was 142,589,662.08 yuan, making up 14.48% of total revenue, down by 8.38% [2] - Revenue from instrument disinfection services increased by 21.88% to 260,737,788.23 yuan, representing 26.48% of total revenue [2] - Other business revenues totaled 21,782,269.33 yuan, down by 3.76% [2] Profitability Analysis - The net profit attributable to shareholders was -105,565,367.23 yuan, a significant decline of 193.80% compared to the previous year [3] - The major reasons for the loss included inventory write-downs of 16,913,000 yuan due to unsold stock and a fair value loss of 87,144,700 yuan on equity investments [3] - The non-recurring net profit was -65,305,422.66 yuan, down 205.93% year-on-year, indicating severe impacts on core business profitability [4] - Basic earnings per share turned negative at -0.1472 yuan, a drop of 193.76% from the previous year [5] - Non-recurring earnings per share also fell significantly, reflecting challenges in core operations [6] Expense Management - Sales expenses decreased by 18.28% to 158,992,708.83 yuan due to reduced market promotion costs following the procurement policy [7][8] - Management expenses increased by 18.95% to 192,042,349.26 yuan, primarily due to expansion-related costs in a subsidiary [9] - Financial expenses surged by 162.99% to 4,209,261.14 yuan, attributed to reduced interest income and exchange losses [10] - R&D expenses were reduced by 27.03% to 43,304,384.54 yuan, reflecting cost control measures in response to the procurement policy [11] Cash Flow Analysis - Operating cash inflow totaled 1,128,947,149.87 yuan, down 10.42% year-on-year, with a net cash flow from operating activities of 157,752,381.96 yuan, a decrease of 42.48% [13][14] - Investment cash inflow increased by 116.43% to 1,759,887,245.92 yuan, while cash outflow rose by 128.27% to 2,282,215,370.06 yuan, resulting in a net cash outflow of -522,328,124.14 yuan [13][15] - Financing cash inflow increased by 77.13% to 321,956,821.60 yuan, with a net cash flow from financing activities of 69,855,182.16 yuan, up 139.49% [13][16] Human Resources and R&D - The number of R&D personnel decreased by 13.46% to 90, with a decline in the proportion of R&D staff to 7.29% [12] - The educational background of R&D staff shifted, with an increase in bachelor's degree holders and a decrease in master's degree holders, potentially impacting innovation capabilities [12] Overall Assessment - The company faces multiple challenges, including significant net losses, fluctuating expenses, and cash flow volatility, necessitating strategic adjustments to enhance operational efficiency and risk management [21]

证券代码：300326 证券简称：ST 凯利 公告编号：2025-047 上海凯利泰医疗科技股份有限公司 关于第六届董事会第七次会议决议公告的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《第六届董事会第七次会议 决议公告》（公告编号：2025-046），经公司事后复核，因发现部分内容需要更 正，具体如下（更正部分加粗表示）： 更正前： 3、审议通过了《关于续聘李元平先生为公司副总经理、财务总监的议案》 公司拟继续聘任李元平先生担任公司的副总经理，财务总监，任期三年。 李元平先生简历如下： 本议案已经第六届董事会审计委员会第二次会议审议通过。 更正后： 3、审议通过了《关于续聘李元平先生为公司副总经理、财务总监的议案》 公司拟继续聘任李元平先生担任公司的副总经理，财务总监，任期三年。 李元平先生，1979 年 8 月出生，现任公司董事、副总经理、财务总监，中 国国籍，无境外居留权，本科学历，中国注 ...

Financial Performance - The net profit attributable to shareholders for 2024 was -105.5654 million RMB, a decrease of 193.80% year-on-year, while the net profit after deducting non-recurring gains and losses was -65.3054 million RMB, down 205.93% compared to the previous year[5]. - The company's operating revenue for 2024 was ¥984,518,762.54, representing a 2.96% increase compared to ¥956,259,537.45 in 2023[20]. - The cash flow from operating activities decreased by 42.48% to ¥157,752,381.96 in 2024 from ¥274,260,691.58 in 2023[20]. - The total assets at the end of 2024 were ¥3,350,848,951.38, a slight decrease of 0.09% from ¥3,354,004,114.33 at the end of 2023[20]. - The company reported a basic and diluted earnings per share of -¥0.1472 for 2024, compared to ¥0.1570 in 2023, marking a decline of 193.76%[20]. - The company's weighted average return on equity was -3.77% in 2024, down from 4.02% in 2023[20]. - The company's non-recurring losses impacted net profit attributable to shareholders by -40.26 million yuan, compared to a gain of 50.89 million yuan in the previous year[61]. Inventory and Impairment - The company recognized inventory impairment losses of 16.9130 million RMB due to changes in market demand and product updates, as well as a significant valuation fluctuation in equity investments, leading to a total profit reduction of 225.6240 million RMB for the year[6]. - The company has engaged a third-party evaluation agency to assess the fair value of long-term equity investments and other non-current financial assets, resulting in an impairment provision of 121.5663 million RMB[6]. - The company recognized inventory impairment of 16.91 million yuan and long-term equity investment impairment of 121.57 million yuan due to market demand changes and valuation fluctuations[61]. Market and Industry Trends - The orthopedic medical device industry in China is experiencing rapid growth, with a significant increase in domestic companies due to the entry of foreign firms and improved technology and management practices[33]. - The average price reduction for orthopedic trauma products in a centralized procurement initiative reached 88.65%, with specific products like the ordinary bone plate system seeing a drop from approximately ¥4683 to ¥606, a decrease of 87.05%[34][35]. - The centralized procurement for orthopedic spinal products resulted in an average price drop of 84%, indicating a significant impact on market pricing and competition[36]. - The implementation of centralized procurement policies is anticipated to reduce patient financial burdens and standardize medical practices, while also pushing smaller companies out of the market[38]. - The orthopedic industry is expected to see a concentration of market share among leading domestic companies, enhancing their competitive advantage[39]. Strategic Initiatives and Future Plans - The company plans to focus on product innovation and explore new materials and technologies to adapt to the changing market landscape and procurement policies[40]. - Cost control measures will be reinforced, including reducing labor costs and operational expenses, to maintain profitability amid declining margins[39][40]. - The company aims to enhance production efficiency and scale to lower production costs, ensuring competitiveness in a low-margin environment[39][40]. - The company plans to integrate existing sales channels and enhance collaboration across product lines to create a multi-brand sales network targeting hospital markets[127]. - International market expansion efforts will be intensified, leveraging overseas subsidiaries to penetrate various regions and enhance brand recognition among clinical practitioners[129]. Research and Development - R&D investment totaled 43.98 million yuan, a decrease of 27.12% year-on-year, accounting for 4.47% of current operating revenue, down 1.84 percentage points from the previous year[64]. - The company aims to strengthen its R&D focus on orthopedic minimally invasive surgical products to maintain a competitive edge in the market[64]. - The company is working on multiple R&D projects, including a new expandable interbody fusion device aimed at enhancing its spinal product line and obtaining FDA registration[83]. - The company plans to expand its trauma product line with new models of locking plates and screws, which are expected to enhance competitiveness in the market[83]. Governance and Management - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability in its operations[157]. - The company established a performance evaluation incentive system linking management compensation to business performance[164]. - The company continues to maintain a diverse board composition, which is essential for effective decision-making and corporate governance[182]. - The company is focusing on enhancing its management team with experienced professionals from various sectors[184]. - The leadership changes are expected to align with the company's long-term growth strategy and operational goals[184]. Risks and Challenges - The company is facing significant risks due to the drastic changes in the external financing environment and the comprehensive collection of orthopedic consumables[5]. - The company anticipates increased market competition in the orthopedic sector, necessitating timely product launches with higher technical content to maintain profit margins[140]. - The company faces inventory impairment risks as it transitions from a dealer stocking model to a production model based on market sales planning, necessitating improved inventory management to avoid excess stock[150]. - The company is exposed to regulatory and policy risks, including price reduction trends in medical devices due to national procurement policies, which may challenge its market competitiveness[145].

证券代码：300326 证券简称：ST 凯利 公告编号：2025-048 上海凯利泰医疗科技股份有限公司 关于《2024年年度报告》的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"凯利泰"或"公司"）于 2025 年 4 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年度报告》 全文，因年度报告工作期间工作量大，且公司编制年度报告相关文件的时间紧迫， 公司《2024 年年度报告》全文有部分内容有误，现对该部分内容予以更正，相 关内容如下： | 会议届次 | 会议类型 | 投资者参与比例 | 召开日期 | 披露日期 | 会议决议 巨潮资讯网， | | --- | --- | --- | --- | --- | --- | | | | | | | 《2023 年度 | | 2023 年度股东大 | 年度股东大会 | 17.78% | 2024 年 05 月 22 | 2024 年 05 月 22 | 股东大会决议公 | | 会 | | | 日 | 日 | 告》（公 | | | ...

Group 1 - The People's Bank of China has established a stock repurchase and increase loan tool, leading to a significant rise in listed companies' repurchase activities, with a total proposed loan amount exceeding 110 billion yuan by April 2025 [1] - On May 7, 2023, the People's Bank of China announced a combined usage of 500 billion yuan for securities, funds, and insurance company swaps, along with 300 billion yuan for stock repurchase loans, totaling 800 billion yuan, while also reducing the interest rate on structural monetary policy tools by 0.25 percentage points to 1.5% [1] - Industry insiders expect a resurgence in stock repurchase activities among listed companies in the near future [1] Group 2 - In January 2023, 60 listed companies conducted stock repurchases, followed by 48 in February, 61 in March, 54 in April, and 34 so far in May [3] - Palin Bio led the increase in repurchase activities with 55 instances, totaling 187,800 shares and an investment of 3.96 million yuan [3] - Other notable companies include Jerry Shares with 25 repurchase instances totaling 255,300 shares and 8.67 million yuan, and Lexin Technology with 23 instances totaling 137,689 shares and 7.51 million yuan [3] Group 3 - Seven executives from various companies increased their holdings by over 10 million shares, including Wu Mingwu from Shanying International and Zhou Xiaoping from Xingyu Shares [5] - Wu Mingwu increased his holdings by 62,151,200 shares across three transactions, amounting to 109 million yuan [7] - Lin Pusheng from Dazhong Mining increased his holdings by 56,695,300 shares for a total of 194 million yuan [7] Group 4 - ST companies are also actively repurchasing their stocks, including ST Kelly, ST Yifei, ST Saiwei, and *ST Jinshi [9] - ST Kelly's chairman, Yuan Zheng, increased his holdings by 4,365,100 shares, totaling 33.09 million yuan [11] - ST Yifei's executives also participated in repurchases, with Vice President Zhao Laigen and Chairman Wu Xuan increasing their holdings by 75,135 shares and 52,013 shares, respectively [12]

第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日以邮件方式向公司各董事发出关于召开第六届董事会第七次会议的通知，并于 2025 年 5 月 11 日 20 时以通讯方式召开会议。本次董事会会议应出席的董事 6 名，实际出席会议的董事 6 名，董事王冲、金诗强、惠一微、张斌、朱丁敏、狄 朝平均以通讯表决方式出席会议。会议由董事长王冲先生主持，公司部分高级管 理人员列席会议。本次会议的召集、召开符合《中华人民共和国公司法》和《上 海凯利泰医疗科技股份有限公司章程》等相关规定。 二、董事会会议审议情况 证券代码：300326 证券简称：ST 凯利 公告编号：2025-046 上海凯利泰医疗科技股份有限公司 1、审议通过了《关于聘任王冲先生为公司总经理的议案》 公司拟聘任王冲先生担任公司的总经理，任期三年。 王冲简历如下：王冲，男，1981 年 8 月出生，迈阿密大学生物医学工程系 博士、加州大学尔湾分校材料科学与化学工程系硕士。王 ...